CODX

Events Bring Together Global Health Leaders to Examine Tuberculosis and Preparedness for the Next Respiratory Pandemic SALT LAKE CITY, Sept. 23, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that Seth Egan, Chief Commercialization Officer, will represent the Company at two global health events during the 81st Session of the United Nations General Assembly in New York City: UNOPS Hosted Partnerships Reception – September 23, 2026: The Company will attend a reception, convened by UN Under-Secretary-General and UNOPS Executive Director Jorge Moreira da Silva, that brings together UNOPS leadership with executives and board members from across its hosted partnerships, including the Stop TB Partnership.

SALT LAKE CITY, Sept. 17, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it will participate in the upcoming joint WHO/Unitaid/UNAIDS Annual Consultation Meeting.

Co-Diagnostics, Inc. (CODX) Shareholder/Analyst Call Transcript

Blood-based testing could open new markets for the Co-Dx® PCR platform, including HIV and hepatitis B and C Co-Diagnostics and ReadyGo target decentralized Ebola detection as the first application of their collaboration Combining GoCollect® sample preparation with Co-Dx PCR technology could bring blood-based molecular testing closer to patients Company to hold in-person press conference and live webcast today at 10:30 a.m. ET SALT LAKE CITY, Sept.

Media, analysts and investors are welcome to attend in person or via live webcast, Sept. 16 at 10:30 a.m.

Two full laboratory installations completed in Florida; installation and customer training underway in Indiana State surveillance has recorded 73 locally acquired dengue cases and identifies 14 dengue-positive mosquito pools in Florida this season SALT LAKE CITY, Sept. 10, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the completion of two new Vector Smart® mosquito surveillance laboratory installations in Florida, with installation and customer training underway at an additional laboratory in Indiana.

Localized cloud environment is designed to support ongoing clinical studies and establish the digital foundation for future data commercialization strategies SALT LAKE CITY, Sept. 3, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the launch of its integrated cloud infrastructure in India.

Shipments of laboratory equipment and other mosquito abatement materials to overseas USAF base represent first international expansion of Vector Smart product line SALT LAKE CITY, Sept. 1, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the first international deployment of its Vector Smart® mosquito surveillance platform, to include shipments of laboratory equipment, consumables, and other mosquito abatement reagents and materials to an overseas United States Air Force ("USAF") base.

Company Chief Commercialization Officer represented Co-Dx in an event featuring other industry stakeholders held on August 13 in Salt Lake City, UT SALT LAKE CITY, Aug. 18, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that Company Chief Commercialization Officer Seth Egan recently participated in the Salt Lake Business Journal's 2026 Medical Devices and Innovation Roundtable event, held on Thursday, August 13 and moderated by the intellectual property law firm Maschoff Brennen in Salt Lake City, Utah. The 90-minute event included discussion of topics such as the significance of recent innovations and challenges surrounding the medical device industry in Utah, the current and future impact of artificial intelligence on the industry, how data interoperability is shaping product development and forecasts for adoption, and what factors are currently shaping companies' strategies in bringing technologies from concept to commercialization.

Advancing Commercialization Through FDA Submission, Global Clinical Progress and Manufacturing Expansion Strengthening Integrated Co-Dx PCR Platform Through Scientific Innovation, Cloud Connectivity and AI-Enabled Capabilities SALT LAKE CITY, Aug. 13, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx," or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced its financial results for the second quarter ended June 30, 2026. Second Quarter 2026 Business Highlights: Advanced CoMira Diagnostics' manufacturing strategy in the Kingdom of Saudi Arabia through Saudi approval for a manufacturing facility industrial site and execution of a lease agreement in Sudair Industrial City, supporting planned localized production and future commercialization across the Middle East and North Africa (MENA) Expanded commercial outreach through participation in a European trade mission with the Utah Governor's Office and World Trade Center Utah, while showcasing the Co-Dx PCR platform and CE-IVD solutions at ESCMID Global 2026 to engage prospective customers, distributors, and strategic partners Presented the Co-Dx PCR tuberculosis (TB) platform at the Stop TB Partnership Summit in Washington, D.C.